Disease‐free survival
Study	Survival % year 1	Survival % year 2	Survival % year 3	Survival % year 4	Survival % year 5	Median survival	Survival p‐value
Izumi 1994	Surgery: 43% Adjuvant: 65%	Surgery: 22% Adjuvant: 55%	Surgery: 12% Adjuvant: 32%	Surgery: 6% Adjuvant: 25%	Surgery: 0% Adjuvant: 6%	Surgery: 1.3 years Adjuvant: 2.3 years	p = 0.0237 (Adjuvant: doxorubicin + mitomycin +/‐ transarterial embolization)
Lai 1998	Surgery: 69% Adjuvant: 50%	Surgery: 53% Adjuvant: 36%	Surgery: 48% Adjuvant: 18%	Surgery: 48% Adjuvant: 6%	Not given	Surgery: 2.5 years Adjuvant: 1.0 year	p = 0.04 (Adjuvant: epirubicin+cisplatin)
Lau 1999	Surgery: 60% Adjuvant: 86%	Surgery: 38% Adjuvant: 75%	Surgery: 38% Adjuvant: 75%	Surgery: 38% Adjuvant: 75%	Surgery: 38% Adjuvant: 50%	Surgery: 1.8 years Adjuvant: not reached	p=0.037 (Adjuvant: lipiodol‐iodine‐131)
Nishiguchi 2005	Surgery: 72% Adjuvant: 92%	Surgery: 60% Adjuvant: 67%	Surgery: 20% Adjuvant: 67%	Surgery: 20% Adjuvant: 67%	Surgery: 20% Adjuvant: 67%	Surgery: 2.6 years Adjuvant: not reached	p=0.055 (adjuvant: interferon‐alpha)
Ono 1997	Surgery: 89% Adjuvant: 68%	Surgery: 70% Adjuvant: 45%	Surgery: 42% Adjuvant: 32%	Surgery: 28% Adjuvant: 32%	Surgery: 0% Adjuvant: 32%	Surgery: 2.5 years Adjuvant: 2.0 years	p = 0.07302 (Adjuvant: epirubicin+oral HCFU)
Takayama 2000	Surgery: 65% Adjuvant: 85%	Surgery: 48% Adjuvant: 70%	Surgery: 33% Adjuvant: 48%	Surgery: 28% Adjuvant: 42%	Surgery: 22% Adjuvant: 40%	Surgery: 2.0 years Adjuvant: 3.0 years	p=0.008 (Adjuvant: immunotherapy)
Wu 1995	Surgery: 70% Adjuvant: 65%	Surgery: 55% Adjuvant: 45%	Surgery: 50% Adjuvant: 40%	Surgery: 50% Adjuvant: 32%	Surgery: 45% Adjuvant: 20%	Surgery: 3.0 years Adjuvant: 1.5 years	p = 0.27 (Neoadjuvant: doxorubicin+TACE)
Yamamoto 1996	Stage I: Surgery: 80% Stage I: Adjuvant: 90% Stage II: Surgery: 75% Stage II: Adjuvant: 70%	Stage I: Surgery: 60% Stage I: Adjuvant: 70% Stage II: Surgery: ‐ Stage II: Adjuvant: 30%	Stage I: Surgery: 30% Stage I: Adjuvant: 70% Stage II: Surgery: ‐ Stage II: Adjuvant: 15%	Stage I: Surgery: 30% Adjuvant: 50% Stage II: Not given	Stage I: Surgery: 19% Adjuvant: 50% Stage II: Not given	Stage I: Surgery: 2.0 years Stage I: Adjuvant: 5.5 years Stage II: Surgery: 1.5 years Stage II: Adjuvant: 1.5 years	STAGE I: p = 0.04 STAGE II: p = 1.00 (Adjuvant: oral 1‐hexylcarbamoyl 5‐fluorouracil (HCFU))
Yamasaki 1996	Surgery: 85% Adjuvant: 85%	Surgery: 60% Adjuvant: 65%	Surgery: 40% Adjuvant: 55%	Surgery: 35% Adjuvant: 48%	Surgery: 30% Adjuvant: 40%	Surgery: 2.0 years Adjuvant: 3.0 years	Not significant (Neoadjuvant: doxorubicin+TACE)